Search research articles
Contact Us
Filters
Showing results (31-40 of 157) with videos related to
Page
of 16
Sort By:
Journal of Medical Economics
|
September 4, 2020
Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore
Mohamed Ismail Abdul Aziz, Wayne Yong Xiang Foo, Chee Keong Toh, et al.
Translational Lung Cancer Research
|
February 9, 2026
Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review
Ross A Soo, Darren Wan-Teck Lim, James Chih-Hsin Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Truth about ERCC1 in lung cancer
Daniel S-W Tan, Quan-Sing Ng, Iain B-H Tan, et al.
Oral Oncology
|
September 23, 2023
Response to fam-Trastuzumab-Deruxtecan in patients with metastatic HER2-positive salivary duct carcinoma: A case series
Jaryl Jia Hao Boey, Kennedy Yao Yi Ng, Cindy Krisnadi, et al.
Expert Review of Anticancer Therapy
|
November 25, 2022
Immunotherapy with chemotherapy and anti-angiogenic therapy for <i>EGFR</i> mutated NSCLC: challenging the dogma
Aaron C Tan, Keigo Kobayashi, Stephanie P L Saw, et al.
Acta Oncologica (Stockholm, Sweden)
|
October 6, 2007
Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer
Richard Quek, Wan Teck Lim, Kian Fong Foo, et al.
Advances in Experimental Medicine and Biology
|
June 1, 2017
Personalized Treatment Through Detection and Monitoring of Genetic Aberrations in Single Circulating Tumor Cells
Swee Jin Tan, Trifanny Yeo, Sarvesh Abhay Sukhatme, et al.
BMC Cancer
|
March 29, 2018
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
Ping-Tee Tan, Mohamed Ismail Abdul Aziz, Fiona Pearce, et al.
Critical Reviews in Oncology/Hematology
|
November 27, 2009
Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status
Joanne Ngeow, Swan Swan Leong, Fei Gao, et al.
Frontiers in Public Health
|
December 19, 2022
Dietary factors and the risk of lung cancer by epidermal growth factor receptor mutation status and histological subtypes
Xin Yin, Gillianne Geet Yi Lai, Adeline Seow, et al.
Page
of 16
Search research articles
Search
Showing results (31-40 of 157) with videos related to
Sort By:
Page
of 16
Journal of Medical Economics
|
September 4, 2020
Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore
Mohamed Ismail Abdul Aziz, Wayne Yong Xiang Foo, Chee Keong Toh, et al.
Translational Lung Cancer Research
|
February 9, 2026
Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review
Ross A Soo, Darren Wan-Teck Lim, James Chih-Hsin Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Truth about ERCC1 in lung cancer
Daniel S-W Tan, Quan-Sing Ng, Iain B-H Tan, et al.
Oral Oncology
|
September 23, 2023
Response to fam-Trastuzumab-Deruxtecan in patients with metastatic HER2-positive salivary duct carcinoma: A case series
Jaryl Jia Hao Boey, Kennedy Yao Yi Ng, Cindy Krisnadi, et al.
Expert Review of Anticancer Therapy
|
November 25, 2022
Immunotherapy with chemotherapy and anti-angiogenic therapy for <i>EGFR</i> mutated NSCLC: challenging the dogma
Aaron C Tan, Keigo Kobayashi, Stephanie P L Saw, et al.
Acta Oncologica (Stockholm, Sweden)
|
October 6, 2007
Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer
Richard Quek, Wan Teck Lim, Kian Fong Foo, et al.
Advances in Experimental Medicine and Biology
|
June 1, 2017
Personalized Treatment Through Detection and Monitoring of Genetic Aberrations in Single Circulating Tumor Cells
Swee Jin Tan, Trifanny Yeo, Sarvesh Abhay Sukhatme, et al.
BMC Cancer
|
March 29, 2018
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
Ping-Tee Tan, Mohamed Ismail Abdul Aziz, Fiona Pearce, et al.
Critical Reviews in Oncology/Hematology
|
November 27, 2009
Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status
Joanne Ngeow, Swan Swan Leong, Fei Gao, et al.
Frontiers in Public Health
|
December 19, 2022
Dietary factors and the risk of lung cancer by epidermal growth factor receptor mutation status and histological subtypes
Xin Yin, Gillianne Geet Yi Lai, Adeline Seow, et al.
Page
of 16